Life Sciences Times, Author at Boston Life Sciences Times

eClinical Solutions Appoints Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer

March 13, 2026

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

March 5, 2026

THIS WEEK'S STORIES

FDA Grants Priority Review to ENHERTU for High-Risk HER2-Positive Early Breast Cancer

March 9, 2026

WHOOP Expands Health Platform with Women’s Blood Biomarker Panel and New Cycle Insights Tools

March 10, 2026

Allurion Appeals NYSE Delisting Decision as It Pursues Plan to Regain Listing Compliance

March 13, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

KORU Medical Systems Secures EU MDR Certification for Freedom60 Infusion Pump With Prefilled Syringe Compatibility

OpenFold Consortium Releases Major OpenFold3 Update and Public Training Data for Biomolecular AI

Allurion Appeals NYSE Delisting Decision as It Pursues Plan to Regain Listing Compliance

eClinical Solutions Appoints Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer

EDITOR PICKS

eClinical Solutions Appoints Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

THIS WEEK'S STORIES

FDA Grants Priority Review to ENHERTU for High-Risk HER2-Positive Early Breast Cancer

WHOOP Expands Health Platform with Women’s Blood Biomarker Panel and New Cycle Insights Tools

Allurion Appeals NYSE Delisting Decision as It Pursues Plan to Regain Listing Compliance

POPULAR CATEGORY

ABOUT US

FOLLOW US